Rocket Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable
Rocket Pharmaceuticals, Inc. (RCKT) reported Increase (Decrease) in Accounts Payable of -$1.14 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2018-03-07
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2017-12-31 was $68.00K.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2017-09-30 was $15.00K, a 98.25% decline year-over-year.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2017-06-30 was -$1.53M.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2017-03-31 was $310.00K.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2017 was -$1.14M.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2016 was -$41.00K, a 108.42% decline from fiscal 2015.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2015 was $487.00K, a 46.89% decline from fiscal 2014.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2014 was $917.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2017-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $83.00K derived: sum of 2 quarters · filed 2018-03-07 | -$1.45M derived: sum of 3 quarters · filed 2018-03-07 | -$1.14M 10-K · filed 2018-03-07 |
| 2017-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$1.52M derived: sum of 2 quarters · filed 2017-11-08 | -$1.21M 10-Q · filed 2017-11-08 | -$1.39M derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-06-30 | -$1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$1.22M 10-Q · filed 2017-08-03 | -$1.41M derived: sum of 3 quarters · filed 2018-03-07 | -$553.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-03-31 | $310.00K 10-Q · filed 2017-05-10 | $125.00K derived: sum of 2 quarters · filed 2018-03-07 | $981.00K derived: sum of 3 quarters · filed 2018-03-07 | $526.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-12-31 | -$185.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $671.00K derived: sum of 2 quarters · filed 2018-03-07 | $216.00K derived: sum of 3 quarters · filed 2018-03-07 | -$41.00K 10-K · filed 2018-03-07 |
| 2016-09-30 | $856.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $401.00K derived: sum of 2 quarters · filed 2017-11-08 | $144.00K 10-Q · filed 2017-11-08 | $68.00K derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | -$455.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$712.00K 10-Q · filed 2017-08-03 | -$788.00K derived: sum of 3 quarters · filed 2017-08-03 | $108.00K derived: sum of 4 quarters · filed 2017-08-03 |
| 2016-03-31 | -$257.00K 10-Q · filed 2017-05-10 | -$333.00K derived: sum of 2 quarters · filed 2017-05-10 | $563.00K derived: sum of 3 quarters · filed 2017-05-10 | $76.00K derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | -$76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $820.00K derived: sum of 2 quarters · filed 2017-03-16 | $333.00K derived: sum of 3 quarters · filed 2017-03-16 | $487.00K 10-K · filed 2017-03-16 |
| 2015-09-30 | $896.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $409.00K derived: sum of 2 quarters · filed 2016-11-09 | $563.00K 10-Q · filed 2016-11-09 | $661.00K derived: sum of 4 quarters · filed 2016-11-09 |
| 2015-06-30 | -$487.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | -$333.00K 10-Q · filed 2016-08-10 | -$235.00K derived: sum of 3 quarters · filed 2016-08-10 | $454.00K derived: sum of 4 quarters · filed 2016-08-10 |
| 2015-03-31 | $154.00K 10-Q · filed 2016-05-11 | $252.00K derived: sum of 2 quarters · filed 2016-05-11 | $941.00K derived: sum of 3 quarters · filed 2016-05-11 | $1.11M derived: sum of 4 quarters · filed 2016-05-11 |
| 2014-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $787.00K derived: sum of 2 quarters · filed 2016-03-23 | $953.00K derived: sum of 3 quarters · filed 2016-03-23 | $917.00K 10-K · filed 2016-03-23 |
| 2014-09-30 | $689.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $855.00K derived: sum of 2 quarters · filed 2015-11-12 | $819.00K 10-Q · filed 2015-11-12 | |
| 2014-06-30 | $166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $130.00K 10-Q · filed 2015-08-07 | ||
| 2014-03-31 | -$36.00K 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |